Vera Therapeutics, INC 8-K filings

Vera Therapeutics has entered into an underwriting agreement for a public offering of 8,064,517 shares of its Class A common stock, expected to generate gross proceeds of approximately $250 million.

Vera Therapeutics reported a preliminary cash balance of $160.7 million as of December 31, 2023, and suspended its at-the-market stock offering.

Vera Therapeutics reported positive 72-week data from its Phase 2b ORIGIN trial, showing atacicept's potential as a disease-modifying treatment for IgA nephropathy.